Skip to main content

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

Written by Customer Service on . Posted in Public Companies.

WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Kimberly Lathroum has joined the company as Vice President of Marketing. In this new role, Ms. Lathroum will be responsible for all of Arcutis’ marketing efforts as the Company prepares for the potential future commercialization of its product candidates.
“Kimberly is an exceptional marketing and commercialization executive with over 18 years of experience in the biopharmaceutical industry, 10 of which have been specifically focused on the dermatology market,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “Her previous success and innovation in brand positioning and commercial launch strategy will be a tremendous asset should we achieve clinical and regulatory success with our robust pipeline of potentially best-in-class dermatology product candidates.”Previously, Ms. Lathroum was Executive Director, Marketing for Kite Pharma. Before that she was Associate Vice President of Marketing for City of Hope. Prior to that, she served in multiple marketing executive roles with Amgen, primarily for dermatology products. Ms. Lathroum holds a B.A. in English, with a minor in Marketing.About Arcutis – Bioscience, applied to the skin.
Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.Contact:
John W. Smither
Chief Financial Officer
jsmither@arcutis.comInvestors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.